The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Newleos is announcing a new member of its Board of Directors and the initiation of Phase 1b clinical studies with NTX-1955 in ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of ...